Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Aclaris Therapeutics Inc (ACRS) on January 4 and set a price target of $50. The company’s shares closed yesterday at $7.71, close to its 52-week low of $6.15.
Chen commented:
“We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.”
According to TipRanks.com, Chen is a 3-star analyst with an average return of 2.2% and a 35.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Aclaris Therapeutics Inc is a Moderate Buy with an average price target of $42.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.25 and a one-year low of $6.15. Currently, Aclaris Therapeutics Inc has an average volume of 604.8K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address unmet needs in medical and aesthetic dermatology and immunology. It operates thrpough Dermatology Therapeutics and Contract Research segments.
